Investigational Site Number 840014

Washington D.C., District of Columbia 20037

0 studies enrolling now · 1 studies all time

What they study most

Relapsing-remitting Multiple Sclerosis

Studies at this site

• Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis — Stopped early